Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment

Transfusion Medicine Reviews

Volumn 24, Issue 3, 2010, Pages 195-210

  Barros, Melca M O ^a,b   Blajchman, Morris A ^a,b   Bordin, José O ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AUTOANTIGEN; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; ERYTHROCYTE ANTIGEN; GLUCOCORTICOID; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINCRISTINE; VITAMIN D; MONOCLONAL ANTIBODY;

ANTIGEN PRESENTATION; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; CARDIOVASCULAR RISK; CATARACT; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; HUMAN; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; MENTAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; OSTEOPOROSIS; PATHOGENESIS; PLASMAPHERESIS; POLYCLONAL ACTIVATION; REGULATORY T LYMPHOCYTE; REVIEW; SPLENECTOMY; T LYMPHOCYTE; WEIGHT GAIN; ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOIMMUNITY; BLOOD TRANSFUSION; IMMUNOLOGY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; BLOOD TRANSFUSION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPLENECTOMY;

EID: 77955108899     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2010.03.002     Document Type: Review

References (112)

1. Packman C.H. Hemolytic anemia due to warm autoantibodies. Blood Rev 2008, 22:17-31.
2. Petz L.D., Garratty G. Immune hemolytic anemia 2004, Elsevier Inc, Philadelphia, PA. ed 2.
3. Gehrs B.C., Friedberg R.C. Autoimmune hemolytic anemia. Am J Hematol 2002, 69:258-271.
4. Genty I., Michel M., Hermine O., et al. Caractéristiques des anémies hémolytiques auto-immunes de l'adulte: Analyse rétrospective d'une série de 83 patients. Rev Méd Interne 2002, 23:901-909.
5. Conley C.L., Lippman S.M., Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980, 244:1688-1690.
6. Barker R.N., Casswell K.M., Reid M.E., et al. Identification of autoantigens in autoimmune haemolytic anaemia by a non-radioisotope immunoprecipitation method. Br J Haematol 1992, 82:126-132.
7. Barker R.N., Elson C.J. Red blood cell glycophorins as B and T-cell antigens in canine autoimmune haemolytic anaemia. Vet Immunol Immunopathol 1995, 47:225-238.
8. Barker R.N., Casswell K.M., Elson C.J. Identification of murine erythrocyte autoantigens and cross-reactive rat antigens. Immunology 1993, 78:568-573.
9. Leddy J.P., Falany J.L., Kissel G.E., et al. Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies. J Clin Invest 1993, 91:1672-1680.
10. Barker R.N., Elson C.J. Multiple self epitopes on the Rhesus polypeptides stimulate immunologically ignorant human T cells in vitro. Eur J Immunol 1994, 24:1578-1582.
11. Barker R.N., Hall A.M., Standen G.R., et al. Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia. Blood 1997, 90:2701-2715.
12. Elson C.J., Barker R.N., Thompson S.J., et al. Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol Today 1995, 16:71-76.
13. Hall A.M., Ward F.J., Shen C.R., et al. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: Effects on autoantibody and T-helper responses. Blood 2007, 110:4511-4517.
14. Oldenborg P.A., Zheleznyak A., Fang Y.F., et al. Role of CD47 as a marker of self on red blood cells. Science 2000, 288:2051-2054.
15. Oldenborg P.A., Gresham H.D., Chen Y., et al. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 2002, 99:3500-3504.
16. Ahrens N., Pagenkopf C., Kiesewetter H., et al. CD47 is expressed at normal levels in patients with autoimmune haemolytic anaemia and/or immune thrombocytopenia. Transfus Med 2006, 16:397-402.
17. Barros M.M., Yamamoto M., Figueiredo M.S., et al. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha, beta on monocytes from patients with warm autoimmune hemolytic anemia. Transfusion 2009, 49:154-160.
18. Yazdanbakhsh K. Controlling the complement system for prevention of red cell destruction. Curr Opin Hematol 2005, 12:117-122.
19. Cohen J.H., Geffriaud C., Caudwell V., et al. Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS 1989, 3:397-399.
20. Birmingham D.J. Erythrocyte complement receptors. Crit Rev Immunol 1995, 15:133-154.
21. Miwa T., Zhou L., Hilliard B., et al. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 2002, 99:3707-3716.
22. Molina H., Miwa T., Zhou L., et al. Complement-mediated clearance of erythrocytes: Mechanism and delineation of regulatory roles of Crry and DAF. Blood 2002, 100:4544-4549.
23. Richaud-Patin Y., Pérez-Romano B., Carrillo-Maravilla E., et al. Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus. Immunol Letters 2003, 88:95-99.
24. García-Valladares I., Atisha-Fregoso Y., Richaud-Patin Y., et al. Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia. Lupus 2006, 15:600-605.
25. Ruiz-Argüelles A., Llorente L. The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun Rev 2007, 6:155-161.
26. Ohashi P.S., DeFranco A.L. Making and breaking tolerance. Curr Opin Immunol 2002, 14:744-759.
27. Hawiger D., Inaba K., Dorsett Y., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
28. Barker R.N., Vickers M.A., Ward F.J. Controlling autoimmunity-Lessons from the study of red blood cells as model antigens. Immunol Lett 2007, 108:20-26.
29. Liu G.Y., Fairchild P.J., Smith R.M., et al. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995, 3:407-415.
30. Playfair J.H.L., Marshall-Clarke S. Induction of red cell autoantibodies in normal mice. Nature New Biol 1973, 243:213-214.
31. Oliveira G.G., Hutchings P.R., Roitt I.M., et al. Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies. Clin Exp Immunol 1994, 96:297-302.
32. Naysmith J.D., Ortega-Pierres M.G., Elson C.J. Rat erythrocyte-induced antierythrocyte autoantibody production and control in normal mice. Immunol Rev 1981, 55:55-87.
33. Theophilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv Immunol 1985, 37:269-273.
34. Musaji A., Meite M., Detalle L., et al. Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. Autoimmun Rev 2005, 4:247-252.
35. Bordin J.O., Kerbauy J., Souza-Pinto J.C., et al. Quantitation of red cell-bound IgG by an enzyme-linked antiglobulin test in human immunodeficiency virus-infected persons. Transfusion 1992, 32:426-429.
36. Vilela R.B., Bordin J.O., Chiba A.K., et al. RBC-associated IgG in patients with visceral leishmaniasis (kala-azar): A prospective analysis. Transfusion 2002, 42:1442-1447.
37. Toriani-Terenzi C., Fagiolo E. IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia. Ann N Y Acad Sci 2005, 1051:29-44.
38. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
39. Shen C.R., Mazza G., Perry F.E., et al. T-helper 1 dominated responses to erythrocyte Band 3 in NZB mice. Immunology 1996, 89:195-199.
40. Adorini L. The pathogenic role of IL12 in TH1-mediated autoimmune diseases. Immunol Immunopharm 2000, 20:29-35.
41. Jacob C.O., van der Meide P.H., McDevitt H.O. In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987, 166:798-803.
42. Shen C.R., Youssef A.R., Devine A., et al. Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood 2003, 102:3800-3806.
43. Youssef A.R., Shen C.R., Lin C.L., et al. IL-4 and IL-10 modulate autoimmune haemolytic anaemia in NZB mice. Clin Exp Immunol 2005, 139:84-89.
44. Ishida H., Munchamuel T., Sakaguchi S., et al. Continuous administration of anti-IL10 antibodies delay onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
45. Fagiolo E., Vigevani F., Pozzetto U. High cytokine serum levels in patients with autoimmune hemolytic anemia (AIHA). Immunol Invest 1994, 23:449-456.
46. Liu T.F., Jones B.M. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998, 10:140-147.
47. Horwitz D.A., Gray J.D., Behrendsen S.C., et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998, 41:838-844.
48. Fagiolo E., Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL-10/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA). Autoimmunity 2002, 35:39-44.
49. Hall A.M., Ward F.J., Vickers M.A., et al. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood 2002, 100:4529-4536.
50. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
51. Torgerson T.R. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 2006, 28:63-76.
52. Hsieh C.S., Zheng Y., Liang Y., et al. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat Immunol 2006, 7:401-410.
53. Willerford D.M., Chen J., Ferry J.A., et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3:521-530.
54. + regulatory T cells control induction of autoimmune hemolytic anemia. Blood 2005, 105:3746-3748.
55. Ward F.J., Hall A.M., Cairns L.S., et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 2008, 111:680-687.
56. Petz L.D. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 2004, 124:712-716.
57. Salama A., Berghöfer H., Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992, 340:1515-1517.
58. Branch D.R., Petz L.D. Detecting alloantibodies in patients with autoantibodies. Transfusion 1999, 39:6-10.
59. Wallhermfechtel M.A., Pohl B.A., Chaplin H. Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion 1984, 24:482-485.
60. Shirey R.S., Boyd J.S., Parwani A.V., et al. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002, 42:1435-1441.
61. Reid M.E. Overview of molecular methods in immunohematology. Transfusion 2007, 47:10S-16S.
62. Rosse W.F. Quantitative immunology of immune hemolytic anemia: II. The relationship of cell-bound antibody to hemolysis and the effect of treatment. J Clin Invest 1971, 50:734-743.
63. Fries L.F., Brickman C.M., Frank M.M. Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol 1983, 131:1240-1245.
64. McDonough A.K., Curtis J.R., Saag K.G. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008, 20:131-137.
65. Valent P., Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: A clinical review. Wien Klin Wochenschr 2008, 120:136-151.
66. Coon W.W. Splenectomy in the treatment of hemolytic anemia. Arch Surg 1985, 120:625-628.
67. Hill J., Walsh R.M., McHam S., et al. Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia: A case series and review of the literature. Am J Hematol 2004, 75:134-138.
68. Pomp A., Gagner M., Salky B., et al. Laparoscopic splenectomy: A selected retrospective review. Surg Laparosc Endosc Percutan Tech 2005, 15:139-143.
69. Balagué C., Targarona E.M., Cerdán G., et al. Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis. Surg Endosc 2004, 18:1283-1287.
70. Newland A., Provan D., Myint S. Preventing severe infection after splenectomy. BMJ 2005, 331:417-418.
71. Pignon J.M., Poirson E., Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993, 83:343-345.
72. Ahn Y.S. Efficacy of danazol in hematologic disorders. Acta Haematol 1990, 84:122-129.
73. Darabi K., Abdel-Wahab O., Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: The Massachusetts General Hospital data and a review of the literature. Transfusion 2006, 46:741-753.
74. Flores G., Cunningham-Rundles C., Newland A.C., et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: Results in 73 patients. Am J Hematol 1993, 44:237-242.
75. Besa E.C. Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. Am J Med 1988, 84:691-698.
76. Bussel J.B., Cunningham-Rundles C., Abraham C. Intravenous treatment of autoimmune hemolytic anemia with very high dose gammaglobulin. Vox Sang 1986, 51:264-269.
77. Majer R.V., Hyde R.D. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin Lab Haematol 1988, 10:391-395.
78. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008, 141:149-169.
79. Taylor R.P., Lindorfer M.A. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008, 20:444-449.
80. Quartier P., Brethon B., Philippet P., et al. Treatment of childhood autimmune haemolytic anemia with rituximab. Lancet 2001, 358:1511-1513.
81. Zecca M., Nobili B., Ramenghi U., et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003, 101:3857-3861.
82. Rao A., Kelly M., Musselman M., et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008, 50:822-825.
83. Kumar S., Benseler S.M., Kirby-Allen M., et al. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics123 2009, 159-163.
84. Svahn J., Fioredda F., Calvillo M., et al. Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants. Br J Haematol 2009, 145:96-100.
85. Gupta N., Kavuru S., Patel D., et al. Rituximab-based chemotherapy for steroid refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leuk 2002, 16:2092-2095.
86. Trapè G., Fianchi L., Lai M., et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003, 88:223-225.
87. Shanafelt T.D., Madueme H.L., Wolf R.C., et al. Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clinic Proc 2003, 78:1340-1346.
88. Zaja F., Vianelli N., Sperotto A., et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003, 44:1951-1955.
89. Narat S., Gandla J., Hoffbrand A.V., et al. Rituximab in the treatment of refractory autoimmunecytopenias in adults. Haematologica 2005, 90:1273-1274.
90. D'Arena G., Laurenti L., Capalbo S., et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006, 81:598-602.
91. D'Arena G., Califano C., Annunziata M., et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: A retrospective study of 11 adult patients. Eur J Haematol 2007, 79:53-58.
92. Bussone G., Ribeiro E., Dechartres A., et al. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases. Am J Hematol 2009, 84:153-157.
93. Kaufman M., Limaye S.A., Driscoll N., et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009, 23:1-8.
94. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004, 72:79-88.
95. Willis F., Marsh J.C., Bevan D.H., et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001, 114:891-898.
96. Marsh J.C., Gordon-Smith E.C. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001, 3:189-195.
97. Cheung W.W., Hwang G.Y., Tse E., et al. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006, 91:ECR13.
98. Karlsson C., Hansson L., Celsing F., et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007, 21:511-514.
99. Laurenti L., Tarnani M., Efremov D.G., et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007, 21:1819-1821.
100. Royer B., Vaida I., Etienne A., et al. Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab. Leukemia 2007, 21:1841-1842.
101. Moyo V.M., Smith D., Brodsky I., et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002, 100:704-706.
102. Shvidel L., Sigler E., Shtalrid M., et al. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: Rethinking old cures. Am J Hematol 2006, 81:423-425.
103. Liu H., Shao Z., Jing L. The effectiveness of cyclosporine A in the treatment of autoimmune hemolytic anemia and Evans syndrome. Zhonghua Xue Ye Xue Za Zhi 2001, 22:581-583.
104. Emilia G., Messora C., Longo G., et al. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 1996, 93:341-344.
105. Cortes J., O'Brien S., Loscertales J., et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer 2001, 92:2016-2022.
106. Zimmer-Molsberger B., Knauf W., Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet 1997, 350:1003-1004.
107. Howard J., Hoffbrand A.V., Prentice H.G., et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002, 117:712-715.
108. Kotb R., Pinganaud C., Trichet C., et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: A single center preliminary study. Eur J Haematol 2005, 75:60-64.
109. Rao V.K., Dugan F., Dale J.K., et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005, 129:534-538.
110. Passweg J.R., Rabusin M. Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity 2008, 41:660-665.
111. McLeod B.C. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias. Curr Opin Hematol 2007, 14:647-654.
112. Ruivard M., Tournilhac O., Montel S., et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. J Clin Apher 2006, 21:202-206.